TCGA-CN-5366-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.082191781
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.490
- HEDGEHOG_SIGNALING+0.410
- WNT_BETA_CATENIN_SIGNALING+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- COAGULATION+0.300
- APICAL_JUNCTION+0.270
- CHOLESTEROL_HOMEOSTASIS+0.230
- MYOGENESIS+0.230
- UV_RESPONSE_DN+0.220
- PROTEIN_SECRETION+0.210
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- TNFA_SIGNALING_VIA_NFKB-0.290
- ESTROGEN_RESPONSE_LATE-0.200
- OXIDATIVE_PHOSPHORYLATION-0.190
- ESTROGEN_RESPONSE_EARLY-0.150
- UV_RESPONSE_UP-0.150
- BILE_ACID_METABOLISM-0.130
- G2M_CHECKPOINT-0.120
- KRAS_SIGNALING_DN-0.110
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0471_T1A_RNA | — | C | 0.748 |
| 2 | ERR2278864 | — | — | 0.683 |
| 3 | SRR2932815 | — | — | 0.672 |
| 4 | b83d70ab.05fd.49f1.bcae.ea9ce0add52f | — | cohortMD2 | 0.668 |
| 5 | SRR5088914 | — | — | 0.664 |
| 6 | TCGA-34-5928-01A-11R-1820-07 | — | cohortSQ1 | 0.661 |
| 7 | SRR5903555 | — | cohortSQ1 | 0.641 |
| 8 | SRR26320091 | — | — | 0.638 |
| 9 | TCGA-XF-AAMT-01A-11R-A42T-07 | — | — | 0.637 |
| 10 | s0122188 | — | — | 0.636 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |